said antimicrobial compound further comprises by weight from about 2% to about 12% folic acid providing a nutrient; and

said folic acid cooperates with said Commiphora myrrha and said Echinacea purpurea to help treat human immunedeficiency virus.

Claim 37. (new) A method for use in treating human immunedeficiency virus in accordance with claim 35, wherein said antimicrobial compound is systemically applyied with a syringe into a rectal canal or vagina of a patient infected with human immunedeficiency virus.

Remarks

Reconsideration and further examination of the above-identified patent application in light of the present Amendment, Reply, and Remarks is respectfully requested.

A Petition for an extension of time is enclosed along with the required extension fee.

Authorization is hereby given to charge any deficiency in fees or any other fees in connection with the above-identified patent application to our Deposit Account No. 23-0920.

Applicant confirms the election of Group III for claims 31-34 drawn to a method of treating HIV.

Applicant reserves the right to seek patent protection in any subsequent divisional application for Group I claims 1-24 drawn to a composition and for Group II claims 25-30 drawn to a method of treating diseases.

Claims 1-34 were pending prior to this Amendment.

Claims 32-34 have been canceled.

Claims 1-30 have been withdrawn.

The matters objected to in claims 31-34 have been corrected or canceled as per the Primary Examiner's requests in order to make the claims more definite and clear and better comply with 35 USC 112.

Claim 31 has been amended to more particularly point out and distinguish applicants' invention over the references of record. Antecedent basis and support for the amended matter in claim 31 is found in the specification and original claims.

New claims 35-37 have been added.

Claims 31 and 35-37 are presently pending for the consideration of the Primary Examiner.

A timely filed terminal disclaimer is enclosed in compliance with 37 CFR 1.321(c) to overcome an actual or provisional rejection based on the nonstatutory double patenting ground. As indicated in the terminal disclaimer, the conflicting patent is commonly owned with this application.

Claim 31 as amended now contains most of the method steps, features and limitations of claim 1 of applicant's U.S. Patent No. 6,350,784.

New claim 35 contains most of the method steps, features and limitations of claim 2 of applicant's U.S. Patent No. 6,350,784.

New claims 36 and 37 are directly dependent on claim 35 and, therefore, also require contains most of the method steps, features and limitations of claim 2 of applicant's U.S. Patent No. 6,350,784, as well as recite additional method steps, features and limitations.

The references of Tyler, Bourbon et al. and Bryant et al. do not disclose applicant's method for use in treating HIV as now specified in amended claim 31 and new claims 35-37. Applicant's amended claim and new claims now contain numerous method steps, features and limitations that are not disclosed in Tyler, Bourbon et al. and Bryant et al.

In summary, applicant's method, as recited in the amended claim and new claims, provides a very useful and user friendly method to treat HIV, which is not anticipated or obvious from Tyler, Bourbon et al., and Bryant et al.

Since the preceding amendment complies with the Primary Examiner's requests, cures the Primary Examiner's objections and patentably distinguishes applicant's remaining claims over the cited prior art references of record, it is respectfully submitted

that the above-identified application is now in condition for allowance. A Notice of Allowance is respectfully requested.

The Primary Examiner is invited and encouraged to contact the undersigned attorney in order to expedite this application to allowance, if the preceding does not already place the above-identified application in condition for allowance.

Respectfully submitted,

Thomas W. Tolpin

Registration Number 27,600 Attorney for Applicant

Address:

Welsh & Katz, Ltd. 22nd Floor 120 South Riverside Plaza Chicago, IL 60606

Phone: (312) 655-1500